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368:709–18.ReplyDabigatran’s ‘Real-World’ Data About
Risk of Myocardial Infarction and
Gastrointestinal Bleeding Contradicts
With Randomized Trials
Dr. Sipahi and colleagues express concern about the discrepancy of
our observational study with randomized controlled studies, and
point to residual confounding as a possible explanation. We have
already discussed these issues in the paper (1), but will expand on
our discussion in the following paragraph.
In observational studies of intended drug effects or safety,
substantial confounding (by indication) is to be expected because
the perceived risk is often closely related to the physician’s choice
of treatment (2). Where there is confounding, there is also the
possibility of residual confounding. Taken to the extreme, hetero-
geneity in risk factors (measured or unmeasured) between treat-
ment groups in key risk factors is a possible explanation for the
observed associations. However, “possible” need not mean “plau-
sible.” Indeed, a careful choice of methods and principles can
mitigate confounding concerns in observational studies (3).
In our study, we adopted a new-user design to ensure that mean-
ingful comparisons were made (4). We explored both propensity
score matching and regression-based confounder adjustment and
found no appreciable differences between these approaches. Last, wefound reassurance in the fact that estimates changed only modestly
upon adjustment for key risk factors for the outcome. Any unmea-
sured confounders would have to be very strongly associated with
treatment and outcome in order for estimates and conclusions to
change qualitatively (5). While it is possible that such unmeasured
confounders exist, we do not consider it very plausible.
There can be other explanations for the discrepancies between
observational and randomized studies (6), which seem more
plausible here. For example, differences in length of follow-up
may result in different conclusions. Also, randomized controlled
trials are externally valid only for the type of patients included in
that trial. Our observational study represents a “real world” pop-
ulation, in which patients had a lower stroke risk cohort compared
with the RE-LY (Randomized Evaluation of Long-Term Anti-
coagulation Therapy) trial (7) participants (mean CHADS2 scores
of 1.2 and 2.1, respectively), and correspondingly, a lower
myocardial infarction risk as well. Also, our patients had a lower
prevalence of prior myocardial infarction or fewer risk factors for
the same (e.g., diabetes mellitus, hypertension), compared with
the RE-LY trial.
In their letter, Sipahi et al. proclaim randomized trials as the gold
standard for drug efﬁcacy and safety assessments. While random-
ized controlled trials are indeed the gold standard in the sense of
providing “fair” comparisons, they may not always provide the most
relevant comparisons. Well-designed observational studies can
address the question whether drug treatment works in daily clinical
practice, not just whether the drug by itself works in ideal settings.
Careful consideration of all the available evidence (randomized and
observational) should be considered the gold standard for post-
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Echocardiographic Instrument
and Methodology Used to Detect
and Quantify the Vegetation on
Implantable Electronic Device?
We have read with interest the study by Narducci et al. (1)
comparing transesophageal echocardiography (TEE) and intracar-
diac echocardiography (ICE) for the diagnostic assessment of
cardiac device-related vegetation. Narducci et al. (1) concluded that
ICE provided improved imaging of right-sided leads and increased
the diagnostic yield of identifying attached vegetations compared
with TEE. However, there are several critical questions related to
their instrument, and their methodology needs to be clariﬁed.
What type of ICE equipment was used? The AcuNav ICE
catheter (Siemens Medical Solutions distributed by Biosense
Webster, Diamond Bar, California) using the Sequoia ultrasound
system (Acuson Corporation, Mountain View, California) with
sector phased array transducer and multifrequency (5.5, 7.5, 8.5,
and 10 MHz) has higher imaging resolution and electronic calipers
for distance measurement. The other ICE catheter using the
Cypress ultrasound system (Siemens Medical Solutions)(a simple,
portable type) has a transducer with fewer ultrasonic frequencies
and a lower imaging resolution, as well as limited caliper measuring
capabilities as compared to the Sequoia system. The description
Narducci et al. (1) provided of their ICE instrument is confusing.
In their methods, they describe using a linear (rather than sec-
tor?) “phased array multifrequency (5.5 to 10 MHz) trans-
ducer.connected to a Sequoia system.” In their discussion section,
however, they discuss using a 9 MHz probe: “These results could
be explained by the major resolution power of the intracardiac
probe (9 vs. 5 MHz).” However, the 9 MHz is not an available
option on the AcuNav and Sequoia platform but may be available
with the Cypress ultrasound system. In our experience, ultrasonic
frequency of 9 MHz or 10 MHz is too high to image small
vegetation or thrombus on a device lead in the deep of the right
atrium or right ventricle (>5 cm to 10 cm). In addition, their
2 ICE images (Fig. 1B and Fig. 2C in their article) all show that
Narducci et al. (1) used a Cypress, not Sequoia ultrasound system.
In our experience, the ICE with the Cypress ultrasound system isnot as accurate as the Sequoia, with lower imaging resolution
and limited 2-dimensional and Doppler diagnostic measurement
capabilities as compared to the Sequoia. Therefore, it is important
to point out that using the Cypress ultrasound system to detect and
quantify a small mass or vegetation on cardiac implantable elec-
tronic device leads might not be as sensitive as compared to the
Sequoia system.
Finally, Narducci et al. (1) did not report their measurements of
the width of vegetation. Vegetations from infective endocarditis are
generally more thickened, coarse, and loose compared with lead
thrombi, which may be seen in as many as 30% of patients with in-
tracardiac leads (2). The width of the vegetation is, therefore, also an
important measurement to discriminate vegetation from thrombus.
The investigators should be congratulated for reporting a large
number of cases with transvenous lead extraction. However, their
results for comparison with TEE of diagnostic capability for
vegetation/mass have to be questioned because of the confounding
of ICE instruments and methodology insufﬁciency.*Jian-Fang Ren, MD
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Echocardiographic Instrument
and Methodology Used to Detect
and Quantify the Vegetation on
Implantable Electronic Device?
We thank Drs. Ren, Supple, and Marchlinski for their interest in
our study (1) and for their thoughtful comments. The equipment
used for intracardiac echocardiography (ICE) consisted of an
Acuson Cypress system (Acuson-Siemens Inc., Mountain View,
California) and an AcuNav 10F (Siemens Medical Solutions
distributed by Biosense Webster, Diamond Bar, California) or
Soundstar (Biosense Webster) probe with 64 elements phased array
multifrequency transducer. We also performed very few cases with
a Sequoia ultrasound system, although the majority of cases were
